Modified bacterium capable of degrading oxalate, mutant proteins that facilitate oxalate degradation, and methods for their use are disclosed.

A quinoline mercaptoacetate sulfonamide derivative, an intermediate, a pharmaceutical derivative or a formulation, and a preparation method and use therefor, wherein the structure of the quinoline mercaptoacetate sulfonamide derivative is as represented by the following formula (I). A preparation method for a compound containing a structure is also represented by the following formula. Experiments show that the compound has a good inhibitory effect on URAT1 transport uric acid in HEK293 transfected cells, and that the compound has good application prospects in the treatment of hyperuricemia or gout.

##STR00001##

Quinoline compounds and salts, hydrates or solvates serving as a selective uric acid reabsorption inhibitor, can be used in the treatment of hyperuricemia and gout by promoting uric acid to excrete from the body and reducing serum uric acid. Such compounds have the effect of reducing the uric acid in the animal body and human body.

Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals.

The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.

The present invention is related to the use of a separate, sequential or simultaneous combination of at least one urinary acidifier with at least one calcium phosphate crystallization inhibitor for urine acidification, and thus preventing the pH at which supersaturation of calcium phosphate is produced and consequently, renal lithiasis.

The present invention belongs to the pharmaceutical field, and relates to a preparation method for a series of benzimidazole derivatives, their pharmaceutical salts and pharmaceutically acceptable prodrugs, a pharmaceutical composition containing the derivatives, and the uses of the derivatives and pharmaceutical composition in the preparation of antigout drugs and in the treatment of related diseases.

The present invention relates to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a pharmaceutical composition containing the same in reducing uric acid level, preventing or reducing inflammations, and preventing or treating uratic or gouty diseases. In particular, the present invention relates to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a pharmaceutical composition containing the same in the manufacture of a medicament for the treatment or prevention of hyperuricemia, gout, gouty inflammations, pain and uric acid nephropathy. ##STR00001## R.sup.1 represents hydrogen, C.sub.1-4 alkyl or the like. R.sup.2 represents C.sub.1-10 alkyl or the like. R.sup.3 represents halogen or the like.

Provided herein are compositions comprising Sel1-derived peptides thereof, and method of use thereof for the treatment/prevention excess oxalate levels and conditions and diseases related thereto. In particular, peptides comprise Sel-like repeat (SLR) domains and/or tetratricopeptide (TPR) domains and may be linked together or with other peptides or polypeptides to treat/prevent diseases/conditions related to excess oxalate levels, such as hyperoxaluria and/or hyperoxalemia.

Provided herein are compositions comprising Sel1-derived peptides thereof, and method of use thereof for the treatment/prevention excess oxalate levels and conditions and diseases related thereto. In particular, peptides comprise Sel-like repeat (SLR) domains and/or tetratricopeptide (TPR) domains and may be linked together or with other peptides or polypeptides to treat/prevent diseases/conditions related to excess oxalate levels, such as hyperoxaluria and/or hyperoxalemia.